Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Osborne W, Haynes E, Wilson W, Ediriwickrema K, Paterson J, Menne T, El-Sharkawi D, Chan LY, Iyengar S, Davies AJ, Hiew HJ, Kanfer E, Foldes D, Chaganti S, Crosland H, Owen M, Follows G, Santarsieri A, Lawless S, Wilson M, McKay P, Osborn R, Tucker D, Thiebaud CM, Fox CP, Ambrose H, Gleeson M, Lam J, Broom A, Smith J, Wells M, Oldham L, Linton K, Jeffers L, Kuhnl A, Collins G, Qasim J, Shah N, McCulloch R, Baloch M, Cox C, Lewis D, Martin A, Maw KZD, Norman J, Deshani V, Stables V, Preston G, Culligan D, Willan J, Ahearne M, Motiwale R, Dunning L, Fawcett J, Kelsey P, Besley C, Lugthart S, Easton J, Gurung S, Ojie D, Mathew S, Auer R, Townsend W

Open source

DOI: 10.3324/haematol.2026.300569
Published: 2026 May 14
Container: Haematologica
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2026.300569,
  title = {Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.},
  author = {Osborne W and Haynes E and Wilson W and Ediriwickrema K and Paterson J and Menne T and El-Sharkawi D and Chan LY and Iyengar S and Davies AJ and Hiew HJ and Kanfer E and Foldes D and Chaganti S and Crosland H and Owen M and Follows G and Santarsieri A and Lawless S and Wilson M and McKay P and Osborn R and Tucker D and Thiebaud CM and Fox CP and Ambrose H and Gleeson M and Lam J and Broom A and Smith J and Wells M and Oldham L and Linton K and Jeffers L and Kuhnl A and Collins G and Qasim J and Shah N and McCulloch R and Baloch M and Cox C and Lewis D and Martin A and Maw KZD and Norman J and Deshani V and Stables V and Preston G and Culligan D and Willan J and Ahearne M and Motiwale R and Dunning L and Fawcett J and Kelsey P and Besley C and Lugthart S and Easton J and Gurung S and Ojie D and Mathew S and Auer R and Townsend W},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2026.300569},
  url = {https://doi.org/10.3324/haematol.2026.300569}
}

RIS

TY  - JOUR
TI  - Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.
AU  - Osborne W
AU  - Haynes E
AU  - Wilson W
AU  - Ediriwickrema K
AU  - Paterson J
AU  - Menne T
AU  - El-Sharkawi D
AU  - Chan LY
AU  - Iyengar S
AU  - Davies AJ
AU  - Hiew HJ
AU  - Kanfer E
AU  - Foldes D
AU  - Chaganti S
AU  - Crosland H
AU  - Owen M
AU  - Follows G
AU  - Santarsieri A
AU  - Lawless S
AU  - Wilson M
AU  - McKay P
AU  - Osborn R
AU  - Tucker D
AU  - Thiebaud CM
AU  - Fox CP
AU  - Ambrose H
AU  - Gleeson M
AU  - Lam J
AU  - Broom A
AU  - Smith J
AU  - Wells M
AU  - Oldham L
AU  - Linton K
AU  - Jeffers L
AU  - Kuhnl A
AU  - Collins G
AU  - Qasim J
AU  - Shah N
AU  - McCulloch R
AU  - Baloch M
AU  - Cox C
AU  - Lewis D
AU  - Martin A
AU  - Maw KZD
AU  - Norman J
AU  - Deshani V
AU  - Stables V
AU  - Preston G
AU  - Culligan D
AU  - Willan J
AU  - Ahearne M
AU  - Motiwale R
AU  - Dunning L
AU  - Fawcett J
AU  - Kelsey P
AU  - Besley C
AU  - Lugthart S
AU  - Easton J
AU  - Gurung S
AU  - Ojie D
AU  - Mathew S
AU  - Auer R
AU  - Townsend W
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2026.300569
UR  - https://doi.org/10.3324/haematol.2026.300569
ER  -

APA

W, O., E, H., W, W., K, E., J, P., T, M., D, E., LY, C., S, I., AJ, D., HJ, H., E, K., D, F., S, C., H, C., M, O., G, F., A, S., S, L., M, W., P, M., R, O., D, T., CM, T., CP, F., H, A., M, G., J, L., A, B., J, S., M, W., L, O., K, L., L, J., A, K., G, C., J, Q., N, S., R, M., M, B., C, C., D, L., A, M., KZD, M., J, N., V, D., V, S., G, P., D, C., J, W., M, A., R, M., L, D., J, F., P, K., C, B., S, L., J, E., S, G., D, O., S, M., R, A., & W, T. (2026). Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.. Haematologica. https://doi.org/10.3324/haematol.2026.300569

Source records

pubmed · retrieved 2026-09-26T07:58:08.622Z